Cargando…

Peroxisome Proliferator-Activated Receptor Agonists: Do They Increase Cardiovascular Risk?

Cardiovascular disease is a major cause of morbidity and mortality among people with type 2 diabetes mellitus. The peroxisome proliferator-activated receptor (PPAR) agonists have a significant role on glucose and fat metabolism. Thiazolidinediones (TZDs) are predominantly PPARγ agonists, and their p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aljada, Ahmad, Shah, Kshitij Ashwin, Mousa, Shaker A.
Formato:	Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2009
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2729049/ https://www.ncbi.nlm.nih.gov/pubmed/19696948 http://dx.doi.org/10.1155/2009/460764

Ejemplares similares

A Role for Peroxisome Proliferator-Activated Receptor Gamma Agonists in Counteracting the Degeneration of Cardiovascular Grafts
por: Assmann, Anna Kathrin, et al.
Publicado: (2022)

The Renoprotective Actions of Peroxisome Proliferator-Activated Receptors Agonists in Diabetes
por: Thomas, M. C., et al.
Publicado: (2012)

The Agonists of Peroxisome Proliferator-Activated Receptor-γ for Liver Fibrosis
por: Li, Jingjing, et al.
Publicado: (2021)

Enhanced Hepatocarcinogenicity Due to Agonists of Peroxisome Proliferator-Activated Receptors in Senescent Rats: Role of Peroxisome Proliferation, Cell Proliferation, and Apoptosis
por: Youssef, Jihan, et al.
Publicado: (2002)

Selective peroxisome proliferator-activated receptorα modulators (SPPARMα): The next generation of peroxisome proliferator-activated receptor α-agonists
por: Fruchart, Jean-Charles
Publicado: (2013)

Repurposing Peroxisome Proliferator-Activated Receptor Agonists in Neurological and Psychiatric Disorders
por: Sagheddu, Claudia, et al.
Publicado: (2021)

Suppression of Rat Oral Carcinogenesis by Agonists of Peroxisome Proliferator Activated Receptor γ
por: McCormick, David L., et al.
Publicado: (2015)

Synergy between peroxisome proliferator‐activated receptor γ agonist and radiotherapy in cancer
por: Huang, Guodong, et al.
Publicado: (2018)

Molecular Biological and Clinical Understanding of the Statin Residual Cardiovascular Disease Risk and Peroxisome Proliferator-Activated Receptor Alpha Agonists and Ezetimibe for Its Treatment
por: Yanai, Hidekatsu, et al.
Publicado: (2022)

Hepatocellular proliferation in response to agonists of peroxisome proliferator-activated receptor alpha: a role for kupffer cells?
por: Alsarra, Ibrahim A, et al.
Publicado: (2006)

Peroxisome proliferator-activated receptor-γ agonists and diabetes: Current evidence and future perspectives
por: Chiarelli, Francesco, et al.
Publicado: (2008)

Peroxisome proliferator-activated receptor agonists modulate neuropathic pain: a link to chemokines?
por: Freitag, Caroline M., et al.
Publicado: (2014)

Modulation Effect of Peroxisome Proliferator-Activated Receptor Agonists on Lipid Droplet Proteins in Liver
por: Zhu, Yun-Xia, et al.
Publicado: (2016)

Treatment of experimental autoimmune uveoretinitis with peroxisome proliferator-activated receptor α agonist fenofibrate
por: Osada, Miho, et al.
Publicado: (2014)

Antitumor action of the peroxisome proliferator-activated receptor-γ agonist rosiglitazone in hepatocellular carcinoma
por: BO, QI-FU, et al.
Publicado: (2015)

Peroxisome Proliferator Activated Receptor Agonists Modulate Transposable Element Expression in Brain and Liver
por: Ferguson, Laura B., et al.
Publicado: (2018)

Peroxisome Proliferator-Activated Receptors (PPAR)γ Agonists as Master Modulators of Tumor Tissue
por: Heudobler, Daniel, et al.
Publicado: (2018)

Peroxisome Proliferator-Activated Receptor Beta/Delta Agonist Suppresses Inflammation and Promotes Neovascularization
por: Tobita, Yutaro, et al.
Publicado: (2020)

Effects of Selective Peroxisome Proliferator Activated Receptor Agonists on Corneal Epithelial Wound Healing
por: Tobita, Yutaro, et al.
Publicado: (2021)

Structural Biology-Based Exploration of Subtype-Selective Agonists for Peroxisome Proliferator-Activated Receptors
por: Miyachi, Hiroyuki
Publicado: (2021)

Peroxisome proliferator-activated receptor gamma and its natural agonists in the treatment of kidney diseases
por: Sharma, Vinesh, et al.
Publicado: (2022)

Effect of combination treatment of S–amlodipine with peroxisome proliferator-activated receptor agonists on metabolic and cardiovascular parameters in Zucker fa/fa rats
por: Singh, Bhagat, et al.
Publicado: (2014)

Peroxisome Proliferators Activated Receptor (PPAR) agonists activate hepatitis B virus replication in vivo
por: Du, Lingyao, et al.
Publicado: (2017)

Different skeletal effects of the peroxisome proliferator activated receptor (PPAR)α agonist fenofibrate and the PPARγ agonist pioglitazone
por: Syversen, Unni, et al.
Publicado: (2009)

Peroxisome Proliferator-Activated Receptor Gamma in Obesity and Colorectal Cancer: the Role of Epigenetics
por: Motawi, T. K., et al.
Publicado: (2017)

Peroxisome proliferator-activated receptors as stimulants of angiogenesis in cardiovascular disease and diabetes
por: Desouza, Cyrus V, et al.
Publicado: (2009)

Natural product agonists of peroxisome proliferator-activated receptor gamma (PPARγ): a review
por: Wang, Limei, et al.
Publicado: (2014)

Peroxisome proliferator-activated receptor δ agonist attenuates hepatic steatosis by anti-inflammatory mechanism
por: Lee, Mi Young, et al.
Publicado: (2012)

Effects of Peroxisome Proliferator-Activated Receptor-δ Agonist on Cardiac Healing after Myocardial Infarction
por: Park, Jeong Rang, et al.
Publicado: (2016)

Pioglitazone, a Peroxisome Proliferator-Activated Receptor γ Agonist, Suppresses Rat Prostate Carcinogenesis
por: Suzuki, Shugo, et al.
Publicado: (2016)

Peroxisome Proliferator-Activated Receptor α Agonist and Its Target Nanog Cooperate to Induce Pluripotency
por: Lee, Jungwoon, et al.
Publicado: (2018)

Peroxisome proliferator-activated receptor γ agonist suppresses mast cell maturation and induces apoptosis
por: Zhang, Yu, et al.
Publicado: (2017)

Antcins, triterpenoids from Antrodia cinnamomea, as new agonists for peroxisome proliferator-activated receptor α
por: Wang, Yu-Jen, et al.
Publicado: (2018)

Peroxisome proliferator-activated receptor ɣ agonist mediated inhibition of heparanase expression reduces proteinuria
por: Garsen, Marjolein, et al.
Publicado: (2023)

Current Progress on Peroxisome Proliferator-activated Receptor Gamma Agonist as an Emerging Therapeutic Approach for the Treatment of Alzheimer's Disease: An Update
por: Khan, Mahmood Ahmad, et al.
Publicado: (2019)

Comparative Evaluation of Gemcabene and Peroxisome Proliferator–Activated Receptor Ligands in Transcriptional Assays of Peroxisome Proliferator–Activated Receptors: Implication for the Treatment of Hyperlipidemia and Cardiovascular Disease
por: Bisgaier, Charles L., et al.
Publicado: (2018)

Epigenetic Activity of Peroxisome Proliferator-Activated Receptor Gamma Agonists Increases the Anticancer Effect of Histone Deacetylase Inhibitors on Multiple Myeloma Cells
por: Aouali, Nassera, et al.
Publicado: (2015)

Melatonin and Its Metabolites Can Serve as Agonists on the Aryl Hydrocarbon Receptor and Peroxisome Proliferator-Activated Receptor Gamma
por: Slominski, Andrzej T., et al.
Publicado: (2023)

Chondrosarcoma and Peroxisome Proliferator-Activated Receptor
por: Nishida, K., et al.
Publicado: (2008)

Peroxisome Proliferator-Activated Receptor α in Lipoprotein Metabolism and Atherosclerotic Cardiovascular Disease
por: Fuior, Elena Valeria, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_0s4nm0bdjkuf8b5nno392fe0lp